Stock Evaluator: Kardigan, Inc. (KARD)

Kardigan, Inc. KARD

$22.01 1.09 5.21%
August 19, 2026 4:00:00 PM EST November 10, 2021 Volume: 213,463
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI-based tools, real-world clinical data, and cardiac-specific analytics to optimize clinical study design, patient screening, and efficacy tracking. The company incorporates Prolaio’s cardiovascular data collection and analytics platform, which includes FDA-cleared algorithms and high-density patient data, to support drug development and clinical intelligence. The company engages in strategic in-licensing and acquisitions to expand its pipeline of targeted treatments. Kardigan serves biopharmaceutical companies, cardiovascular researchers, and healthcare providers in the cardiology sector. The company was formerly known as EnCarda, Inc. and changed its name to Kardigan, Inc. in December 2024. The company was founded in 2023 and is based in Princeton, New Jersey.

Commentary & Analysis


Financial Summary

Share Statistics KARD Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $1,894.4 $618.0 53%
Shares Out (Mil) 25.2 44.8 34%
Institutional Ownership 67.2% 85.3% 42%
Float (Mil) 51.8 47.4 48%
Beta na 0.70 na
Avg Daily Volume (000s) 221 390 45%
Price Change
(52-week)
na 68.6% na
Growth KARD Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 6.7% na
Net Income (5yr) na (1.6%) na
EPS (5yr) na 14.9% na
Dividends (5yr) na 0.0% na
Cash Flow (5yr) na (14.9%) na
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 3 3 3
Current EPS ($0.735) ($3.892) ($3.132)
Month Ago EPS ($0.695) ($2.925) ($3.012)
# Rev Up na na na
# Rev Down na na na
Three Months Ago EPS na na na
Year/Year Chg (84.1%) (73.8%) (76.7%)
Financials KARD Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $291 na
Net Income (TTM) (Mil) ($289) ($11) 5%
EPS (TTM) ($17.125) ($0.700) 3%
Operating Cash Flow (TTM) (Mil) ($206) ($6) 4%
Net Cash Flow (TTM) (Mil) $316 $5 88%
Long-Term Debt (Q1) (Mil) $10 $6 28%
Enterprise Value (Q1) (Mil) $1,452 $450 45%
Valuation KARD Industry
Median
Percentile
(All Stocks)
P/B 3.07 2.78 65%
P/E na 17.4 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 1.1 na
Ratios KARD Industry
Median
Percentile
(All Stocks)
Gross Margin na 67.0% na
Net Margin na (2.3%) na
ROA (80.0%) (22.4%) 7%
ROE (93.8%) (20.2%) 10%
Liabilities to Assets 14.7% 32.2% 9%
F-Score 1 3 na

Kardigan, Inc. did not pass any screens on 8/20/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors